Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desirudin
Drug ID BADD_D00614
Description Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52. It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients. Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.
Indications and Usage Indicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
Marketing Status Prescription
ATC Code B01AE01
DrugBank ID DB11095
KEGG ID D03692
MeSH ID C060225
PubChem ID 16129703
TTD Drug ID D00UOR
NDC Product Code Not Available
Synonyms desirudin | desulphatohirudin | recombinant HV1 hirudin | desulfatohirudin | Iprivask | IK-HIR02 | CGP 39393 | CGP-39393 | Revasc
Chemical Information
Molecular Formula C287H440N80O110S6
CAS Registry Number 120993-53-5
SMILES CCC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C( =O)NC(CSSCC2C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NCC (=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)C(C)C)CC(=O)N)CO)CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C3 CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N3)CC(C)C)CC(= O)N)CCC(=O)N)CO)CCC(=O)O)C(C)O)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(CC4=CC=C(C= C4)O)NC(=O)C(C(C)C)NC(=O)C(C(C)C)N)C(=O)N1)CCCCN)CC(=O)N)CCC(=O)N)C(=O)NC(C(C)C) C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NCC(=O)NC(C(C)O)C(=O)N5CCCC5C(=O)NC(C CCCN)C(=O)N6CCCC6C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NC(CC7=CN=CN7)C(=O)NC(CC(=O)N) C(=O)NC(CC(=O)O)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC8=CC=CC=C8)C(=O)NC(CCC(=O)O)C(= O)NC(CCC(=O)O)C(=O)NC(C(C)CC)C(=O)N9CCCC9C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O) NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)O)CCC(=O)N)CC(=O)N)CCCCN )CCC(=O)O)CC(=O)O)CO)CC(C)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaemia01.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Bladder pain20.02.02.001--Not Available
Body temperature increased13.15.01.001--Not Available
Burkitt's lymphoma16.28.04.001; 01.15.04.001--Not Available
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cystitis20.03.02.002; 11.01.14.001--
Dermatitis23.03.04.002--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Epistaxis24.07.01.005; 22.04.03.001--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematoma24.07.01.001--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Infection11.01.08.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages